Abstract
Cardiovascular disease is the leading cause of morbidity and mortality in the Western world. However, it appears that currently available risk assessment tools often underestimate risk, especially for patients in the intermediate-risk category. Considering the socioeconomic cost, it is imperative to correctly identify patients in the intermediate-risk category who would benefit from more aggressive treatment. A plethora of experimental and observational studies provide support that lipoprotein associated phospholipase A2 (Lp- PLA2) and secretory phospholipases A2 (sPLA2) as well as high sensitivity C-reactive protein (hsCRP) are useful biomarkers of cardiovascular risk. Particularly, Lp-PLA2) has also been addressed as pharmacological target and we are eagerly awaiting the results of ongoing phase III clinical trials. In this review we discuss the current literature regarding the pros and cons of these biomarkers.
Keywords: Atherosclerosis, biomarkers, cardiovascular disease, hsCRP, inflammation, Lp-PLA2, PAF-acetylhydrolase, sPLA2.
Current Pharmaceutical Design
Title:Inflammatory Biomarkers and Cardiovascular Risk Assessment. Current Knowledge and Future Perspectives
Volume: 19 Issue: 21
Author(s): Elisavet Moutzouri, Vasilis Tsimihodimos and Alexandros D. Tselepis
Affiliation:
Keywords: Atherosclerosis, biomarkers, cardiovascular disease, hsCRP, inflammation, Lp-PLA2, PAF-acetylhydrolase, sPLA2.
Abstract: Cardiovascular disease is the leading cause of morbidity and mortality in the Western world. However, it appears that currently available risk assessment tools often underestimate risk, especially for patients in the intermediate-risk category. Considering the socioeconomic cost, it is imperative to correctly identify patients in the intermediate-risk category who would benefit from more aggressive treatment. A plethora of experimental and observational studies provide support that lipoprotein associated phospholipase A2 (Lp- PLA2) and secretory phospholipases A2 (sPLA2) as well as high sensitivity C-reactive protein (hsCRP) are useful biomarkers of cardiovascular risk. Particularly, Lp-PLA2) has also been addressed as pharmacological target and we are eagerly awaiting the results of ongoing phase III clinical trials. In this review we discuss the current literature regarding the pros and cons of these biomarkers.
Export Options
About this article
Cite this article as:
Moutzouri Elisavet, Tsimihodimos Vasilis and D. Tselepis Alexandros, Inflammatory Biomarkers and Cardiovascular Risk Assessment. Current Knowledge and Future Perspectives, Current Pharmaceutical Design 2013; 19 (21) . https://dx.doi.org/10.2174/13816128113199990307
DOI https://dx.doi.org/10.2174/13816128113199990307 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The New Adipose Tissue and Adipocytokines
Current Diabetes Reviews Development of New Fibrinolytic Agents
Current Pharmaceutical Design Health Benefits of Ipecac and Cephaeline: their Potential in Health Promotion and Disease Prevention
Current Bioactive Compounds Cardioprotective Effects of the Polyphenol Hydroxytyrosol from Olive Oil
Current Drug Targets Obstructive Sleep Apnea Syndrome: Implications in Cardiovascular Disease
Current Respiratory Medicine Reviews Stem Cells as In Vitro Models of Disease
Current Stem Cell Research & Therapy Glucose-6-Phosphate Dehydrogenase Deficiency: Disadvantages and Possible Benefits
Cardiovascular & Hematological Disorders-Drug Targets Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology Medicinal Research Progress of Natural Coumarin and its Derivatives
The Natural Products Journal Adenosine Receptor Ligands-Recent Developments Part I. Agonists
Current Medicinal Chemistry A Conceptual Framework of Comorbidity for Investigation in the Context of Psychiatric Disturbance
Current Psychiatry Reviews Future Targets in Endothelial Biology: Endothelial Cell to Mesenchymal Transition
Current Drug Targets Vascular Effects of Antiarrhythmic Drugs and the Roles of K+ Channels
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Myocardial Contrast Echocardiography: Role in Clinical Cardiology
Current Vascular Pharmacology Segmentation of Short Axis CMR Images Using Hybrid Method
Current Medical Imaging Clozapine Safety, 35 Years Later
Current Drug Safety The MAPK / JNK Signalling Pathway Offers Potential Therapeutic Targets for the Prevention of Acquired Deafness
Current Drug Targets - CNS & Neurological Disorders Chinese Herbal Medicine for Hyperlipidaemia: A Review Based on Data Mining from 1990 to 2016
Current Vascular Pharmacology Low Dose Aspirin, COX-Inhibition and Chemoprevention of Colorectal Cancer
Current Topics in Medicinal Chemistry Anti-Platelet Treatment of Middle-Sized Abdominal Aortic Aneurysms
Current Vascular Pharmacology